Home
Login
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
Research data
DOI
 |
Open Access Gold |
|
as soon as is submitted to ZB.
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.
Lancet Reg. Health-Eur. 65:101722 (2026)
Steatotic liver disease (SLD) is the leading cause of chronic liver disease in Europe, with liver fibrosis representing the strongest predictor of liver-related outcomes and an important contributor to cardiometabolic risk. This Series paper examines diagnostic innovation and models of care to improve fibrosis detection and risk stratification across the continuum of care for SLD. A growing range of non-invasive tests for fibrosis assessment is now available, including blood-based biomarkers, imaging modalities, automated laboratory algorithms, and artificial intelligence-enabled tools. However, implementation remains inconsistent because of limited awareness, restricted geographic and financial access to advanced diagnostics, fragmented referral pathways, heterogeneous reimbursement, limited use of automated reflex testing, and poor digital integration across laboratories and electronic health records. Integrated multidisciplinary models of care linking primary care with specialist services may improve early fibrosis detection, referral efficiency, and equitable access to risk-stratified management, particularly among people living with indicator conditions such as type 2 diabetes and obesity.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Blood-based Biomarkers ; Diagnostic Innovation ; Diagnostic Pathways ; Fibrosis Detection ; Masld ; Metald ; Models Of Care ; Non-invasive Tests ; Precision Hepatology ; Risk Stratification
ISSN (print) / ISBN
2666-7762
e-ISSN
2666-7762
Quellenangaben
Volume: 65,
Article Number: 101722
Publisher
Elsevier
Reviewing status
Peer reviewed